HCC Clinical Trials in Tianjin, Tianjin Municipality
5 recruitingTianjin, Tianjin Municipality, China
Showing 1–5 of 5 trials
Recruiting
Phase 2
Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
HCC - Hepatocellular CarcinomaConversion Therapy
Tianjin Medical University Cancer Institute and Hospital43 enrolled1 locationNCT07560488
Recruiting
Phase 2
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
Hepatocellular Carcinoma (HCC)
Abbisko Therapeutics Co, Ltd141 enrolled51 locationsNCT07327034
Recruiting
Phase 2
Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
HCC
Tianjin Medical University Cancer Institute and Hospital29 enrolled1 locationNCT07099274
Recruiting
Phase 2
HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
Hepato Cellular Carcinoma (HCC)
Fudan University165 enrolled3 locationsNCT06812039
Recruiting
Phase 1
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Advanced Solid TumorNSCLCLymphoma+1 more
Betta Pharmaceuticals Co., Ltd.110 enrolled4 locationsNCT05341557